Making fundamental scientific discoveries by combining information from literature, databases, and computational tools – An example

Bastian Stielow\textsuperscript{a}, Clara Simon\textsuperscript{a}, Robert Liefke\textsuperscript{a,b,*}

\textsuperscript{a} Institute of Molecular Biology and Tumor Research (IMT), Philipps University of Marburg, 35043 Marburg, Germany
\textsuperscript{b} Department of Hematology, Oncology and Immunology, University Hospital Giessen and Marburg, 35043 Marburg, Germany

\textbf{A B S T R A C T}

In recent years, the amount of available literature, data and computational tools has increased exponentially, providing opportunities and challenges to make use of this vast amount of material. Here, we describe how we utilized publicly available information to identify the previously hardly characterized protein SAMD1 (SAM domain-containing protein 1) as a novel unmethylated CpG island-binding protein. This discovery is an example, how the richness of material and tools on the internet can be used to make scientific breakthroughs, but also the hurdles that may occur. Specifically, we discuss how the misrepresentation of SAMD1 in literature and databases may have prevented an earlier characterization of this protein and we address what can be learned from this example.

© 2021 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

\textbf{Contents}

1. Introduction ..................................................................................................... 3027

1.1. Defining a research question ................................................................. 3028

1.2. Finding an unexpected protein ............................................................ 3028

1.3. The pitfalls of using internet search engines ........................................ 3029

1.4. More evidence that SAMD1 could be a novel CpG-binding protein .... 3029

1.5. How to deal with conflicting gene annotations? .................................... 3030

1.6. There is no DNA-binding domain in SAMD1. Really? ......................... 3030

1.7. Secreted, cytoplasmatic, nuclear? ....................................................... 3031

1.8. From research question, to candidate, to experimental validation ....... 3031

1.9. What else can be learned from internet databases? .............................. 3031

2. Conclusion ................................................................................................. 3031

\textbf{CRediT authorship contribution statement} ................................................... 3032

Declaration of Competing Interest .................................................................... 3032

Acknowledgement ......................................................................................... 3032

References ...................................................................................................... 3032

1. Introduction

The function of a cell is mainly dictated by proteins and their interplay. Therefore, the characterization of protein functions during various biological processes is one of the fundamental research tasks in life science. To learn more about proteins and to discover potential novel functions, several alternative strategies can be applied. Often, novel findings build on screening experiments, which are designed to fish out proteins or genes that may play a role in a certain context. Subsequently, the potential candidates are investigated whether they indeed have a function relevant to the original research question. However, novel
discoveries may not always rely on experimental approaches. The enormous increase of literature and data provides the ground to
discover interesting proteins or protein functions solely by the cor-
rect interpretation of these accessible material. Thus, instead of
uncovering candidates by performing specific experiments, it
becomes more and more feasible to search for potential candidates
by investigating publicly available material (Fig. 1).

Here, we present as an example, how the usage of public mate-
rial led to the discovery of a novel CpG island-binding protein,
SAMD1 (SAM domain-containing protein 1). This protein has
hardly been characterized yet, and the information in databases
were partially incomplete or wrong (stand May 2021). This wrong
information may have contributed to the hesitance of researchers
to investigate this protein in more detail. Nonetheless, despite
not much was known about SAMD1, the combination of numerous
hints led to the conclusion that SAMD1 is a strong candidate to be a
novel unmethylated CpG island-binding protein. Based on this data
exploration, we could indeed subsequently confirm our hypothesis
using extensive structural, molecular biological and genome-wide
approaches [1]. In this article, we describe how we detected
SAMD1 in the first place, and how the exploration of publicly avail-
able material and the usage of bioinformatic tools increased our
confidence that SAMD1 is a worthy candidate for in-depth
investigation.

1.1. Defining a research question

To address a specific question, it is essential either to design
appropriate experiments, or to survey the literature and/or public
data towards a specific aspect (Fig. 1). The here discussed research
question emerged from the structural work of the Zhanxin Wang
group, who identified the Polycomb-like proteins as novel proteins
that specifically can bind to unmethylated CpG-motifs [2]. The CpG
-motif is often enriched at so-called CpG islands (CGIs), which are
commonly found at promoters and play important gene regulatory
roles [3]. CGIs are either in a methylated state, which leads to tran-
scriptional silencing, or in an unmethylated state, where the
respective gene is typically actively transcribed. Before the discov-
ery of the Polycomb-like proteins, only the CXXC-domains have
been described to specifically interact with unmethylated, but
not with methylated CpG-motifs [4,5]. Proteins containing
CXXC-domains are often part of larger protein complexes that
can modulate the chromatin status. For example, CXXC1 (CXXC
Finger Protein 1; also CFP1) is a component of the COMPASS
(Complex Proteins Associated with Set1) complex [6], which is
important to establish the active H3K4me3 mark at promoters.
The discovery that besides the CXXC-domain proteins also the
Polycomb-like proteins can bind to unmethylated CpG-motifs,
offered several novel aspects about the regulatory function of the
CGIs. First, this work provided an explanation for the known local-
ization of the Polycomb repressive complex 2 (PRC2) at CGIs [7,8].
Second, it emphasized that unmethylated CGIs can be involved
both in gene activation and gene repression [2]. Thirdly, this work
showed that besides CXXC-domains also other domains can bind to
unmethylated CpG-motifs. The Polycomb-like proteins facilitate
the CpG-binding function via a winged-helix domain. Intriguingly,
the overall fold of the CXXC-domains and the winged-helix domain
is fundamentally different, yet the CpG recognition is remarkably
similar, mainly established by a loop of charged amino acids that
reach into the major groove of the DNA [2]. This finding suggests
that the CpG-motif recognition is more flexible than previously
assumed, and that a CpG-binding loop can possibly be created also
by other domains. Thus, the question arose whether other so far
undescribed proteins or domains may facilitate the interaction
with unmethylated CpG-motifs.

1.2. Finding an unexpected protein

As already numerous studies, which have explored chromatin-
and DNA-binding proteins, are available we wondered whether these
data are sufficient to identify unmethylated CpG-motifs candidates. Thus, instead of establishing and performing an exper-
iment to identify novel CpG-binding proteins, we decided to inves-
tigate first the available material for putative candidates (Fig. 1).
Which criteria may be suitable to identify novel CpG-binding pro-
teins? We assumed that such proteins should be localized nuclear,
associated with chromatin and they should preferentially bind to
unmethylated and CpG-rich DNA. How can such factors be identi-
fied? The easiest way appears to search for publications, in which
proteins are investigated for their preference either for methylated
or for unmethylated DNA. One of the earliest publications in this
regard was Bartke et al. [9], which explored nucleosome-binding
proteins dependent on both, DNA methylation, and histone
modification status using mass-spectrometry. Surveying the
accompanying tables and supplementary figures from this study,
we were looking for proteins that are excluded from nucleosomes
with methylated DNA. Besides known unmethylated CpG-binding
proteins, such as MTF2 (Metal Response Element Binding Tran-
scription Factor 2), FBXL10 (F-Box and Leucine-Rich Repeat Protein
10; also KDM2B), and CXXC5 (CXXC Finger Protein 5), several other
proteins are associated specifically with unmethylated nucleo-
somes. Unexpectedly, those proteins were not only chromatin-associated proteins, but also other less known proteins.
In particular, a protein called “Atherin” (also named SAMD1) drew
our attention, because it belongs to the proteins, which are most
strongly excluded from methylated nucleosomes (Fig. 2A). The
name “Atherin” refers to the first description of this protein, as a
secreted protein involved in atherosclerosis [10]. Besides this one
publication dated almost 20 years ago, no further evidence

---

**Fig. 1.** Outline how a scientific question can be addressed. Besides doing exper-
iments, the investigation of literature and accessible databases may allow to
identify suitable candidates for follow up investigations. Information in databases
is not always reliable and requires careful evaluation. Closer inspection of dismissed
candidates may reveal suitable candidates for an in-depth investigation. After
further validation, utilizing databases and computational tools may provide the
space to follow-up experiments or to develop novel research questions.
supports a role of Atherin in atherosclerosis. The occurrence of Atherin in mass-spectrometry datasets of nucleosome-associated proteins either suggests that it is a contamination or that Atherin may have a completely distinct function than originally described. Given that Atherin is not highly enriched in the CRAPome database [11], which identifies typical contaminants from mass-spectrometry experiments, we speculated that the second possibility could be true. For this reason, we will use the more neutral term “SAMD1” (SAM domain-containing protein 1) for further description of this protein.

1.3. The pitfalls of using internet search engines

To further investigate SAMD1’s potential role at DNA and/or chromatin, we looked for additional publications where SAMD1 is occurring. However, as SAMD1 has hardly been characterized yet, not many publications about SAMD1 are available in the literature databases. The only publications about SAMD1 refer to the SAM–domain function [12], but the authors did not address the role of SAMD1 specifically. Similarly, searching for SAMD1 using internet search engines mainly leads to hits from databases, such as UniProt (universal protein database) or NCBI (National Center for Biotechnology Information), but hardly to any publications. In addition, we recognized that the close similarity of the name to the well-characterized protein SMAD1 (Suppressor of Mothers against Decapentaplegic 1) complicates the search for SAMD1-containing literature, since many hits refer to SMAD1, instead of SAMD1. Also, in not a few number of publications “SAMD1” is misspelled as “SAMD1” leading to false-positive hits. Nonetheless, we found that excluding SMAD1 using “-SMAD1” as additional search criteria, strongly improved the internet search results. Given that SAMD1 has hardly been investigated yet, we speculated that SAMD1 may predominantly occur in large-scale datasets and is perhaps hidden in supplementary data or figures. Since we are mainly interested in the SAMD1 protein, and not its transcript, we searched for protein-related datasets. Indeed, using the search “SAMD1 -SMAD1 mass-spectrometry” led to several interesting findings.

1.4. More evidence that SAMD1 could be a novel CpG-binding protein

One of the found publication was Viturarawong et al. [13], which investigated proteins that bind to ultra-conserved genomic regions. In one figure where the authors systematically analyzed the consequence of transitional DNA changes (A<>G, C<>T) on the DNA-bound proteins via mass-spectrometry, SAMD1 levels were found to be altered upon several DNA changes. To comprehend which transformation of the DNA sequence led to changed SAMD1-binding, we systematically assessed the alteration of the DNA sequence (Fig. 2B). Remarkably, we found that an increase of SAMD1-binding often correlates with the occurrence of novel CpG-motifs (position 12), while a decrease is associated with the disappearance of a CpG-motif (position 27). This pattern is similar to MTF2, one of the Polycomb-like proteins, and CXXC5, a CXXC-domain-containing protein. Other proteins, such as TFAM, show totally different patterns. Further search identified more publications where SAMD1 is found in mass-spectrometry. In Xiong et al. [14], SAMD1 was repelled from hydroxy-methylated DNA (Fig. 2C), while in Perino et al. [15] SAMD1 was pulled-down by CpG-rich DNA (Fig. 2D). Further, SAMD1 has also been found to be affected by mutations of CpG-containing E2F binding motifs [16]. Here, a mutation of a CpG-motif within the E2F binding sites (TTTCCGCA to TTTACA), led to strong reduction of SAMD1 DNA-binding (Fig. 2E). Notably, in many of those publications, SAMD1 and the protein L3MBTL3 behaved rather similar, suggesting that SAMD1 and L3MBTL3 (Lethal(3)malignant brain tumor-like protein 3) are connected. Indeed, in pull-down experiments using SFMBT1 as bait, SAMD1 and L3MBTL3 were

![Fig. 2. A-E) DNA-related occurrences of SAMD1 in the literature [9,13–16]. Those publications cannot be found by standard literature search but were discovered via internet research. In B) only selected parts of the figure are shown and for each column, the creation or disappearance of a CpG-motif upon transitional DNA mutations, is presented by asterisks. For columns 12 and 27 the DNA change is presented below. Together, these publications suggest a preference of SAMD1 for CpG-rich and unmethylated DNA.](image-url)
co-eluted [17], suggesting that they are both parts of a larger protein complex. These data also demonstrate that SAMD1 is likely associated with chromatin-related protein complexes, supporting our original idea.

Altogether, the survey for publications provided several independent evidences that SAMD1 has a preference to interact with unmethylated CpG-motifs (Fig. 2), making it a potential candidate for our original research question.

1.5. How to deal with conflicting gene annotations?

Due to these first hints suggesting that SAMD1 could be a novel CpG-motif binding protein, we aimed to learn more about SAMD1. However, when we attempted to gather further information about SAMD1, we recognized some problems regarding the annotation of the SAMD1 gene. The following information is provided by UniProt (ID: Q6SPF0) [18] about the human SAMD1 gene: “Due to its high GC-content it turned out to be difficult to sequence the 5’ end of the gene encoding the N-terminal proline-rich region of the protein and to unambiguously determine which sequence is correct. We display the sequence described in PubMed: 16159594. This sequence fits better with orthologous sequences but is not consistent with the human reference genome sequence”. So, we had a closer look at the DNA sequence provided by PubMed:16159594 [10], which has been uploaded to NCBI (ID: 38565228). Looking at the sequences, one can easily recognize that the cDNA sequence of SAMD1 is indeed extremely CG-rich, suggesting that sequencing of the SAMD1 gene is not trivial. Consequently, automated genome assembly may have mis-annotated SAMD1, which was then introduced into the databases. Comparing the database entry of human SAMD1 in UniProt and Ensembl (ID: ENSG00000141858) [19] demonstrates the problem. In UniProt, human SAMD1 has a length of 538 amino acids, while in Ensembl it is only 432 amino acids. UniProt refers to the sequence originally described by Lees et al. [10], while Ensembl is based on the automated genome assembly. Interestingly, more recent investigations on the human genome using modern technology, such as SMRT-Seq [20], identified this discrepancy. In several publications [21–23] a 318 bp insertion to the SAMD1 gene is mentioned, which reflects exactly the 106 amino acids difference between the two annotations in UniProt and Ensembl. Thus, we concluded that the 518 amino acids sequence for human SAMD1, as originally described in Lees et al. [10], is likely the correct sequence.

1.6. There is no DNA-binding domain in SAMD1. Really?

Having decided which annotation for SAMD1 we should use for further investigations, it was now important to nail down whether SAMD1 indeed can bind to CpG-rich DNA. Specifically, we asked whether SAMD1 possesses a domain that is suitable for DNA binding. So far only one domain is annotated in SAMD1, namely the C-terminal SAM-domain. SAM-domains are commonly involved in protein–protein interactions and are not typically participating in DNA binding [24], implying the SAM-domain cannot contribute to the potential binding of SAMD1 to CpG-rich sequences. SMART (Simple Modular Architecture Research Tool) [25] and comparable tools showed no other domains in SAMD1, suggesting that the rest of the protein has no region that is similar to known domains. Interestingly, however, the GlobPlot tool [26] predicted an additional globular domain at the N-terminus of SAMD1 (Fig. 3A), suggesting that SAMD1 indeed has another domain, besides its C-terminal SAM-domain. But what kind of domain is it? To address this question, we made use of protein structure prediction software. Remarkably, Phyre2 [27] and SWISS-MODEL [28] predicted with high confidence that the N-terminal globular domain is a winged-helix domain, most similar to histone H1 (Fig. 3A). Interestingly, the primary sequence shows only a very low sequence identity to other winged-helix domains, possibly explaining why this domain has not been identified by other domain prediction software. This example therefore demonstrates that the usage of protein structure prediction software may reveal unannotated domains, that have distinct primary sequences, but a similar fold to known domains.

Thus, this investigation led to the discovery of a putative novel winged-helix domain in SAMD1, which has not been annotated before. Given that the Polycomb-like proteins bind to unmethylated CpG-motifs also via a winged-helix domain [2], we...
speculated that the winged-helix domain of SAMD1 can possibly facilitate interaction to CpG-rich DNA, as well.

1.7. Secreted, cytoplasmatic, nuclear?

As mentioned before, SAMD1 has been described to be a secreted protein [10]. This finding has also been imported into UniProt and other databases (Fig. 3B). In contrast, the Protein Atlas [29], a comprehensive database about proteins, describes the cellular localization of SAMD1 entirely differently. Here, SAMD1 is presented as a cytoplasmatic protein, supported by a strong cytoplasmatic staining using custom-made antibodies (Fig. 3B). On the other hand, the PSORT II software [30] predicts SAMD1 to be nuclear with 78.3 percent confidence. Also, the presence of SAMD1 in several chromatin related publications [17,31,32] supports a nuclear localization of SAMD1. So, where is SAMD1 really localized? Given this discrepancy between the information, we decided ultimately to address this issue experimentally. We created our own SAMD1 antibody [1] and by using immunofluorescence, we found that in all investigated cells, SAMD1 is mostly present in the nucleus (Fig. 3C), confirming the PSORT II prediction. This result disagrees with the Protein Atlas and with the description of SAMD1 to be secreted [10]. How can these contradicting findings be explained? Most likely, the used antibodies may not be fully specific for SAMD1 and therefore the obtained signal reflects something SAMD1-unrelated. Notably, Protein Atlas stainings of SAMD1 in human tissues, which were made with the same antibody as for the cell lines, clearly shows a nuclear localization of SAMD1. Why the same antibody leads to totally different staining in cell lines and tissues has not yet been resolved by the Protein Atlas database.

1.8. From research question, to candidate, to experimental validation

In summary, starting from the question of whether there are more CpG-binding proteins, we explored literature and came across SAMD1 as a potential candidate. It was an unexpected finding, given that SAMD1 has been described to be secreted and to be involved in Atherosclerosis [10]. However, upon closer inspection, we could gather further evidence that this protein is linked to unmethylated CpG-rich DNA (Fig. 2). We also detected a putative winged-helix domain (Fig. 3A) and found that SAMD1 is mainly nuclear (Fig. 3C). Interestingly, none of this information can be found easily, since the data about SAMD1 are either deeply buried in publications, incomplete or wrong. However, our survey led to the conclusion that SAMD1 is a strong candidate for further investigations. Ultimately, we were indeed able to confirm a chromatin regulatory role of SAMD1 at unmethylated CGIs [1]. Together with the group of Zhanxin Wang we could solve the structure of SAMD1’s winged-helix domain with CpG-containing DNA (PDB: 6LU1) and we could demonstrate that SAMD1 binds to a subset of unmethylated CGIs in mouse embryonic stem cells, where it carries out a repression function [1]. Thus, our work could demonstrate that beyond the CXXC-domain proteins and the Polycomb-like proteins indeed further proteins are able to bind unmethylated CGIs, which confirmed our original research question. Notably, SAMD1 is a unique chromatin regulator, because it not only binds to CGIs, but it is also connected to SAM-domain proteins, which play a role in long-range chromatin interactions [33,34]. This combination may allow SAMD1 to facilitate a special function at CGIs. Thus, our discovery will help to better understand CpG island regulation in the future.

1.9. What else can be learned from internet databases?

Despite our structural and molecular biological characterization of SAMD1, many aspects of SAMD1 remain to be explored. What else can be learned about hardly characterized proteins, using the available resources? It is always useful to search for publications, where the gene/protein of interest is mentioned. Many of those publications cannot be found by standard literature search, but instead can only be detected by smart and extensive internet research, given that the relevant information is buried in the figures or the supplementary data. For SAMD1 several publications can be found, where it has been linked to certain diseases. For example, a non-synonymous nonvariant of SAMD1 has been associated via GWAS with the severity of symptoms upon a malaria infection [35]. Thus, it could be interesting to work out what are the consequences of this amino acid alteration for the biological function of SAMD1, and how this influences the response to malaria infection.

Besides looking for specific publications, we recommend making use of the many available databases in the internet to gather information about known or unknown proteins. Basic information about a protein, such as its sequence and annotated domains, are comprehensively included into the UniProt database (www.uniprot.org) [18]. An overview of identified posttranslational modifications (PTMs), such as phosphorylation, methylation, ubiquitylation and sumoylation can be found with PhosphositePlus (https://www.phosphosite.org/) [36]. For SAMD1 several such modifications have been identified (Fig. 4A), which may be important to fine-tune the function of SAMD1. The expression of a gene in human tissues can most easily been assessed using the GTex (Genotype-Tissue Expression) database (https://gtexportal.org/) [37] or the Protein Atlas (https://www.proteinatlas.org) [29]. SAMD1 is expressed in all human tissues (not shown), suggesting a ubiquitous function. The expression of a protein in cancer versus normal tissue can be deduced using the GEPIA platform (http://gepia.cancer-pku.cn/) [38]. An increased expression of SAMD1 in several cancer tissues can be found (Fig. 4B), which may suggest a role of SAMD1 in cancer. The relationship between gene expression and cancer patient survival can be investigated via GEPIA or the Xena Browser (https://xenabrowser.net/) [39]. For example, SAMD1 expression has a strong prognostic value for ACC (adenoid cystic carcinoma) patients (Fig. 4C), further supporting a role of SAMD1 in cancer. Cancer related point mutations are systematically presented in the cBioPortal (https://www.cbioportal.org/) [40], which is useful to identify potentially important regions for the protein function in cancer. Further, the results of CRISPR screen experiments are now included into various databases. For example, the role of proteins for the proliferation of cancer cell lines can be evaluated using DepMap (https://depmap.org/) [41]. Results from more CRISPR-Screens can easily be accessed using BioGRID ORCS (https://orcs.biogrid.org/) [42]. This collection is not exhaustive, and many more databases are available that address specific scientific queries. Information from those databases may allow performing follow-up experiments to investigate further details about the protein of interest or to develop novel research questions (Fig. 1).

2. Conclusion

The example in this article demonstrates the strength and the pitfalls that come with the accessibility and the spread of research data. On one side, it shows the disadvantage of the automatic transfer from large-scale research data into databases, without proper curation. Due to technical challenges, such as the high CG content in the SAMD1 gene, wrong data may get introduced into databases. Those data are also often exchanged from one database to another, leading to an amplification of potentially incorrect information. For example, the (likely) erroneous annotation of SAMD1 with a protein length of 432 amino acids, which has been
obtained during early human genome assemblies [44], is present in several databases, such as Ensembl and the UCSC browser. Currently in remains unclear when the SAMD1 gene will be corrected in the human genome databases and when downstream databases will reprocess their data to update their entries. This will also be relevant for other wrongly annotated genes. In addition, the questionable description of the SAMD1 protein as a secreted protein can also be found in miscellaneous databases. Thus, contradicting, or wrong information from various databases are not easy to recognize and can prevent to investigate potentially interesting proteins. This issue is particularly relevant for researchers that not extensively make use of these databases. The constant occurrence of novel databases, reorganization of established databases, and disappearance of other databases, makes it often difficult to know which databases are still up-to-date and can be trusted.

Besides those general database problems, the naming of SAMD1 as “Atherin” may have led to a misjudging of the protein. “Atherin” sounds like a typical mass-spectrometry contaminant, such as Tubulin or Albumin. SAMD1 may have been dismissed by others as a protein of interest, simply because of its name. Only a more careful investigation can reveal that SAMD1 is much less commonly found in mass-spectrometry experiments than classical contaminants, such as TUBB3 (Tubulin) and ALB (Albumin) [11]. We hope that in the future the neutral name SAMD1 will exclusively be used.

Nonetheless, despite those obstacles, the discovery of SAMD1 is a great example for the opportunities that lay in the enormous amount of freely accessible material. Starting from the initial sighting of SAMD1 in Bartke et al. [9], we were able to identify several additional publications that have mentioned SAMD1, simply by searching the internet. It would have been impossible to find those publications using classic literature search in the library. Also, the presence of SAMD1 in numerous databases provided the ground to investigate this protein in more detail. It allowed to critical assess the available information and to resolve some discrepancies, such as the gene annotation and the cellular localization. Furthermore, the discovery of the winged-helix domain was only possible because of the availability of the protein sequence and structure prediction software [27,28], which substantially improved our confidence in SAMD1. Without those tools, SAMD1 would not have become a candidate for our research question, which probably would have delayed the characterization of SAMD1 as a novel CGI binding protein [1] for a couple of more years.

In summary, our excursion into the discovery of SAMD1 demonstrates that it is not always required to perform experiments to identify potential interesting candidates for a research question. It is possible to find exciting proteins by critical investigating the available literature, databases and by utilizing appropriate tools. Experience with those utilities will permit to exclude unsuitable candidates and to identify interesting candidates, which could allow to skip time-consuming and cost-intensive screening experiments and start directly with validation experiments, as we have done it for SAMD1 [1]. Given that this strategy can possibly accelerate the progress in science, it is advisable to be familiar with common internet databases, and computational tools, to make full use of their potential.

CRediT authorship contribution statement

Bastian Stielow: Investigation, Writing - review & editing.
Clara Simon: Investigation, Writing - review & editing. Robert Liefke: Conceptualization, Investigation, Writing - original draft, Visualization, Supervision, Project administration, Funding acquisition.

Declaration of Competing Interest

The authors declare no conflict of interest.

Acknowledgement

Research on SAMD1 is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – TRR 81/3 – 109546710 and GRK 2573/1 – 416910386, and the Fritz-Thyssen Foundation (Az. 10.201.105). The funders played no role in the writing the article or in the decision to submit the article for publication.

References

[1] Stielow B, Zhou Y, Cao Y, Simon C, Pogoda H-M, Jiang J, et al. The SAM domain-containing protein 1 (SAMD1) acts as a repressive chromatin regulator at unmethylated CpG islands. Sci Adv 2021. https://doi.org/10.1126/sciadv.abd2222 (in press).
[2] G.R. Liefke, R. Jiang, J. Kurland JV, Tian W, Deng P, et al. Polycomb-like proteins link the PRC2 complex to CpG islands. Nature 2017;549(7671):287–91.
[3] Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev. 2011;25(10):1010–22.
[4] Long HK, Blackledge NP, Klose RJ, ZF-CxxC domain-containing proteins, CpG islands and the chromatin connection. Biochim Biophys Acta. 2013;41:727–40.
[5] Xu C, Liu K, Lei M, Yang A, Li Y, Hughes TR, et al. DNA sequence recognition of human CXXC domains and their structural determinants. Structure 2018;26 (5–8):e143.
[6] Clouaire T, Webb S, Skene P, Illingworth R, Kerr A, Andrews R, et al. Cfp1 integrates both CpG content and gene activity for accurate H3K4me3 deposition in embryonic stem cells. Genes Dev 2012;26(15):1714–28.
Mendonhall EM, Koche RP, Truong T, Zhou VW, Issac B, Chi AS, et al. GC-rich sequence elements recruit PRC2 in mammalian ES cells. PLoS Genet 2010;6(12):e1001244.

Jermann P, Hoerner L, Burger L, Schubeler D. Short sequences can efficiently recruit histone H3 lysine 27 trimethylation in the absence of enhancer activity and DNA methylation. Proc Natl Acad Sci U S A 2014;111(33):E3415–21.

Bartke T, Vermeulen M, Xhemalce B, Rohson SC, Mann M, Kouzarides T. Nucleosome-interacting proteins regulated by DNA and histone methylation. Cell 2010;143(3):370–40.

Lees AM, Deconinck AE, Campbell BD, Lees RS. Atherin: a newly identified, lesion-specific, LDL-binding protein in human atherosclerosis. Atherosclerosis 2005;182(2):219–30.

Mellacheruvu D, Wright Z, Couzens AI, Lambert J-P, St Denis NA, Li T, et al. The CRAVome: a contaminant repository for affinity purification-mass spectrometry data. Nat Methods 2013;10(8):730–6.

Knight MJ, Leetola C, Gieorgy M, Li H, Bowie JL. A human sterile alpha motif domain polymerizeome. Protein Sci 2011;20(10):1697–706.

Viturawong T, Meissner F, Butler F, Mann M. A DNA-centric protein interaction map of ultraconserved elements reveals contribution of transcription factor binding hubs to conservation. Cell Rep 2013;5(2):531–45.

Xiong J, Zhang Z, Chen J, Huang H, Xu Y, Ding X, et al. Cooperative action between SALL4A and TET proteins in stepwise oxidation of 5-methylcytosine. Mol Cell 2016;64(5):913–25.

Perino M, van Miero G, Karamender ID, van Genesen P, Vermeulen M, Marks H, et al. MTF2 recruits polycomb repressive complex 2 by helical-shape-selective DNA binding. Nat Genet 2018;50(7):1002–10.

Pestel M, Prill-Schicker C, Webb T, Malik R, Lindner B, Ziesch N, et al. The atherosclerosis risk variant rs2107595 mediates allele-specific transcriptional regulation of HDAC9 via EZF2 and Rbi. Stroke 2019;50(10):2651–60.

Zhang J, Bonasio R, String F, Kluger Y, Holloway JK, Medzelevski AJ, et al. SMRT1 functions with LSD1 to regulate expression of canonical histone genes and chromatin-related factors. Genes Dev 2013;27(7):749–66.

The UniProt Consortium. (2017) UniProt: the universal protein knowledgebase. Nucleic Acids Res 45, D158-D169.

Yates AD, Achurthi P, Akamhi W, Allen J, Alvarez-Jarreta J, Amode MR, et al. Ensembl 2020. Nucleic Acids Res 2020;48:D682–8.

Arduí S, Ameur, A., Vermeesch, J.R. and Hestand, M.S. (2018) Single molecule real-time (SMRT) sequencing: forms of age: applications and utilities for medical diagnostics. Nucleic Acids Res, 46, 2159–2168.

Chaisson MP, Huddleston J, Dennis MY, Sudmant PH, Malig M, Hormozdari F, et al. Resolving the complexity of the human genome using single-molecule sequencing. Nature 2015;517:7536:608–11.

Kronenzen ZN, Fiddes IT, Gordon D, Murali S, Cantsilieris S, Meyerson OS, et al. High-resolution comparative analysis of great ape genomes. Science 2018;360(6393).

Shirota, M. and Kinosita, K. (2016) Discrepancies between human DNA, mRNA and protein reference sequences and their relation to single nucleotide variants in the human population. Database (Oxford), 2016.

Qiao, F. and Bowie, J.U. (2005) The many faces of SAM. Sci STKE, 2005, re7.

Zhang J, Bonasio R, Strino F, Kluger Y, Holloway JK, Modzelewski AJ, et al. Cooperative action between SALL4A and TET proteins in stepwise oxidation of 5-methylcytosine. PLoS Genet 2010;6(10):e1001244.

Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJE. The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc 2010;5(10):845–58.

Waterhouse, A., Bertioli, M., Bieler, S., Studer, G., Tauriello, G., Gumienny, R., Heer, F.T., de Beer, T.A.P., Rempfer, C., Bordoli, L. et al. (2018) SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res, 46, W296-W303.

Uhlen M, Björling E, Agaton C, Szigyarto C-K, Amini B, Andersen E, et al. A protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 2005;4(12):1920–32.

Nakai K, Horton P. PSORT: a program for detecting sorting signals in proteins and predicting their subcellular localization. Trends Biochem Sci 1999;24(1):34–5.

Malovannaya A, Li Y, Bulynko Y, Jung SY, Wang Y, Lanz RB, et al. Streamlined analysis scheme for high-throughput identification of endogenous protein complexes. Proc Natl Acad Sci U S A 2010;107(6):2431–6.

Engelen E, Brandsima JH, Moen MJ, Signorile L, Dekkers DHW, Demmers J, et al. Proteins that bind regulatory regions identified by histone modification chromatin immunoprecipitations and mass spectrometry. Nat Commun 2015;6(1), https://doi.org/10.1038/ncomms8155.

Isono K, Endo T, Ku M, Yamada D, Suzuki K, Sharif J, et al. SAM domain polymerization links subnuclear clustering of PRC1 to gene silencing. Dev Cell 2013;26(6):565–77.

Wanu AH, Boertiger AN, Sc disorder P, Ergun A, Münger C, Sadreayei RI, et al. Chromatin topology is coupled to Polycomb group protein subnuclear organization. Nat Commun 2016;7(1), https://doi.org/10.1038/ncomms10791.

Yamagishi J, Natori A, Tolba MEM, Morgan AE, Sugimoto C, Katayama T, et al. Interactive transcriptome analysis of malaria patients and infecting Plasmodium falciparum. Genome Res 2014;24(9):1433–44.

Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E, PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res 2014;43:D512–520.

Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shah S, et al. The Genotype-Tissue Expression (GTEx) project. Nat Genet 2013;45(6):580–58.

Tang, Z., Li, C., Kang, B., Gao, G. and Zhang, Z. (2017) GEPA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res, 45, W98-W102.

Goldman MJ, Craft B, Hastie M, Repecká K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol 2020;38(6):675–8.

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401–4.

Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a cancer dependency map. Cell 2017;170(3):564–576.e16.

Oughtred R, Stark C, Breetkrezus, B.J., Rust J., Boucher, L., Chang, C., Kolas, N., O'Donnell, L., Leung, G., McAdam, R. et al. (2019) The BioGRID interaction database: 2019 update. Nucleic Acids Res, 47, D529-D541.

Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Ozenberger BA, Elliott K, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013;45(10):1113–20.

Grimwood J, Gordon LA, Olsen A, Terry A, Schmutz J, Lamedin J, et al. The DNA sequence and biology of human chromosome 19. Nature 2004;428(6982):529–35.